Vladimir Zernov
Add to Bookmarks

Pfizer Video 16.04.21.

Pfizer Shares Gain Ground After CEO Says People May Need Booster COVID-19 Shots

Shares of Pfizer gained additional upside momentum after the company’s CEO Alfred Bourla stated that a third shot of the vaccine may be needed within 12 months. He also stated that annual vaccination against coronavirus may be required in the future.

Know where the Market is headed? Take advantage now with 

Trading Derivatives carries a high level of risk to your capital and you should only trade with money you can afford to lose. Trading Derivatives may not be suitable for all investors, so please ensure that you fully understand the risks involved, and seek independent advice if necessary. A Product Disclosure Statement (PDS) can be obtained either from this website or on request from our offices and should be considered before entering into a transaction with us. Raw Spread accounts offer spreads from 0.0 pips with a commission charge of USD $3.50 per 100k traded. Standard account offer spreads from 1 pips with no additional commission charges. Spreads on CFD indices start at 0.4 points. The information on this site is not directed at residents in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

If coronavirus vaccination becomes a source of recurring revenue for Pfizer and other vaccine producers, analysts will have to adjust their earnings estimates to the upside. At this point, it is not clear whether people will need regular vaccination after they receive two shots of COVID-19 vaccine, and analysts are rather conservative in their estimates.

In Pfizer’s case, analysts expect that the company will report earnings of $3.32 per share in 2021 and $3.04 per share in 2022. If analysts come to the conclusion that the world will have to order more doses of the vaccine from Prizer in 2022 and beyond, earnings estimates may be changed materially.


What’s Next For Pfizer?

The recent trading sessions were very successful for producers of messenger RNA – based vaccines – Pfizer/BioNTech and Moderna. The recent news about potential blood clots linked to AstraZeneca and Johnson & Johnson vaccines have provided material support to mRNA-based vaccine makers.

Today, Australia reported its first death from a blood clot which was likely linked to AstraZeneca vaccine. While researchers say that the risk of blood clots from COVID-19 is much higher than the risk of blood clots from vaccines, AstraZeneca and Johnson & Johnson vaccines got a lot of bad press in recent days which will make it harder for governments to order them for the next year and beyond.

In this light, traders may continue to bet that producers of mRNA-based vaccines like Pfizer will gain market share which is bullish for their stocks.

For a look at all of today’s economic events, check out our economic calendar.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker